MedTech tariff strategy in 2026: Section 232 MedTech investigation pending; scope and rate TBD. FDA-CBP regulatory coordination required. Mexican MedTech (Tijuana cluster) and Canadian MedTech can qualify under USMCA. Twin Cities MedTech cluster faces highest concentration of exposure.
This guide covers MedTech Industry Tariff Strategy. Sector-specific tariff strategy considers HS classification patterns, applicable special tariff regimes (Section 232/301/122), and FTA opportunities.
Practical implementation depends on company size, sector, and operational structure.
Section 232 MedTech investigation
Scope and rate pending. Likely sectoral coverage of medical devices, diagnostics, surgical instruments.
FDA-CBP coordination
Devices need both FDA admissibility and CBP entry compliance. Drug-device combos sit at boundary with pharma probe.
USMCA on Mexican MedTech
Tijuana-cluster medical device manufacturers can qualify. RVC analysis required.
Twin Cities MedTech cluster
Medtronic, Boston Scientific, 3M ecosystem faces Section 232 concentration exposure. Tier 2 supplier work is active.
Frequently asked questions
When does this apply?
Most relevant for SMB importers in the named sector or facing the named situation.
What documentation matters?
Standard CBP forms, supplier certificates, BOM analysis, and topic-specific records.
What is the timeline?
Initial assessment 2-4 weeks; full implementation 8-16 weeks depending on scope.
What does this cost?
Project work $5,000-$25,000 depending on complexity. Ongoing retainer for active operations.
How do I begin?
Book a 15-minute scoping call. We confirm fit before any engagement.
Get started
Run a sector-specific tariff exposure assessment for your business.